References
- Paton NI, Stöhr W, Oddershede L, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technol Assess. 2016;20:1–158.
- Bunupuradah T, Kiertiburanakul S, Avihingsanon A, et al. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV. 2016;3:e343–e350.
- Lanzafame M, Lattuada E, Cucchetto G, et al. Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2015;68:e59–e61.
- Lanzafame M, Lattuada E, Cucchetto G, et al. Efavirenz dose reduction in HIV-infected patients: a long-term follow-up. Aids. 2014;28:2789–2790.
- Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir–ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198:234–240.
- Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460–465.
- Butler K, Inshaw J, Ford D, et al. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial. Health Technol Assess. 2016;20:1–108.
- de Truchis P, Assoumou L, Landman R, et al. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2017 Nov 25.
- Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (Lond). 2017;49:1–34.